Preferred Label : Linavonkibart;
NCIt synonyms : Anti-latent TGFb1 Monoclonal Antibody SRK-181; Anti-TGF-beta 1 Monoclonal Antibody SRK-181; Anti-latent TGF-b1 Monoclonal Antibody SRK-181; Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181; SRT-BETA-1-AB3;
NCIt definition : A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta
1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, linavonkibart
specifically targets, binds to, and inhibits the activation of latent TGFb1 complexes,
thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression,
enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic
T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell
death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells.
The TGF-beta signaling pathway is often deregulated in tumors and plays a key role
in the regulation of cell growth, differentiation, apoptosis, motility, invasion,
and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the
predominant isoform in many tumors.;
UNII : 8SSL98OST3;
CAS number : 2640981-30-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2640981-30-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : SRK 181; SRK-181;
NCI Metathesaurus CUI : CL1407357;
Origin ID : C173598;
UMLS CUI : C5774026;
Semantic type(s)
- UMLS correspondences (same concept)
- SRK-181 [MeSH Supplementary Concept]
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
